Response assessment in metronomic chemotherapy: RECIST or PERCIST?
نویسندگان
چکیده
منابع مشابه
Comparing Metabolic and Anatomic Response to Chemotherapy PERCIST and RECIST in Advanced NSCLC
Lung cancer is the leading cause of cancer death worldwide (Jemal et al., 2011). Approximately 80% of primary lung cancers are classified as non-small cell lung cancer (NSCLC) and two thirds of NSCLC patients present with locally advanced or advanced disease that is not amenable to curative surgery (Martin et al.,2002). Patients with stage IV disease are generally treated with systemic therapy....
متن کاملFrom RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
UNLABELLED The purpose of this article is to review the status and limitations of anatomic tumor response metrics including the World Health Organization (WHO) criteria, the Response Evaluation Criteria in Solid Tumors (RECIST), and RECIST 1.1. This article also reviews qualitative and quantitative approaches to metabolic tumor response assessment with (18)F-FDG PET and proposes a draft framewo...
متن کاملCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
Response criteria represent the standard by which the efficacy of therapeutic agents is determined in cancer trials. The most widely used criteria are based on the anatomic measurement of solid tumors. Because bone metastases are typically located in irregularly shaped bones and are difficult to measure with rulers, they have been previously considered unmeasurable disease. New developments in ...
متن کاملMetronomic Capecitabine for Elderly Advanced Gastric Carcinoma Patients Pretreated With One or Two Systemic Chemotherapy Lines
Background: The aim of this study was to investigate the efficacy and safety of metronomic capecitabine chemotherapy in pretreated elderly patients with advanced gastric carsonoma. Patients and Methods: Eligible patients were treated with capecitabine at a fixed dose of 1000mg daily until disease progression or toxicity. Endpoints were overall response rate, safety, progression-free survival...
متن کاملResponse assessment in daily practice: RECIST and its modifications
Response Evaluation Criteria for Solid Tumours (RECIST) were introduced in 2000 to provide a standardized method for assessing response to treatments in the clinical trial setting [1]. The RECIST Working Group has updated RECIST to version 1.1 [2]. The revised version has maintained assessment of tumour burden using sum of the diameters and continues to use uni-dimensional measurements. The res...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Nuclear Medicine
سال: 2014
ISSN: 0972-3919
DOI: 10.4103/0972-3919.130285